glp-1 obesity drug market news today Receptor Agonist Growth Analysis Study predicts 16 new obesity

Clinical indications and comorbidities play a primary role in medication selection

Due to the promotive effect of GLP-1R agonism on -cells proliferation and survival, concerns of tumorigenesis, especially pancreatic cancers, have been raised about incretin-based therapies (89)

these factors may contribute to a higher incidence of hepatobiliary adverse events [2,37]

Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Despite new insulin formulations and improvements in the technology of insulin pumps and continuous glucose monitoring, glycemic control continues to be suboptimal in T1D, with about 80% of patients not reaching the recommended goals

The New York Times